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Introduction
Using personalized or precision medicine (PM) is commonly understood as an approach for the prevention and treatment of diseases that 
takes individual biological variability into account. 
Usually, this is achieved by applying biomarkers, 
enabling stratification of patients or individual dosing, 
for example. However, there is no formal uniform 
standardized definition for PM.
The European Union defines PM rather broadly as: 
to provide the right treatment to the right patient, at the 
right dose at the right time[1]. As a consequence, it might 
be important to identify the major active pharmaceutical 
ingredient within a mixture of compounds used in 
an approved drug. This allows unnecessary, or even 
potentially harmful, drug compounds to be eliminated. 
In 1994, a proprietary combination of fumaric acid 
esters (FAEs) was licensed for the treatment of psoriasis 
by the German Drug Administration for use in Germany. 
Since then, fumarates have been established as one of 
the most commonly used oral treatments for moderate to 
severe psoriasis. The licensed FAE formulation contains 
dimethylfumarate (DMF), calcium, zinc, and magnesium 
salts of monoethylfumarate (MEF). While the clinical 
efficacy of this FAE mixture is well established, the 
combination of esters on which it is based, and its 
dosing regimen, were determined empirically. Since the 
mid-1990s, the modes of action and the contribution of 
the different FAEs to their overall therapeutic effect in 
psoriasis have been investigated in more detail. Here, we 
describe and compare the in vitro data for different FAEs 
that gave insight into the compound — DMF — that is 
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the major active ingredient accounting for the clinical 
effects in psoriasis.
Pharmacological Activity of the FAEs in Pso­
ri a sis
Many in vitro and in vivo studies have attempted to 
clarify the mechanistic effects of each of the components 
of the approved FAE mixture (Fumaderm®), the drug 
most frequently used for oral therapy of psoriasis in 
Germany. Work to elucidate the roles of DMF and 
its main metabolite, monomethylfumarate (MMF), 
and MEF has been carried out in several different cell 
types and has provided a foundation of preclinical 
data on which to understand the effectiveness of DMF 
and the approved FAE mixture in the management of 
psoriasis[2–18]. Results of preclinical experiments with 
DMF, MMF and MEF are shown in Table 1.
However, the in vitro data have to be interpreted 
with caution, because the drug concentrations used in 
several experiments were high and often exceeded the 
concentrations reached in patients many-fold. Indeed, it 
seems that maximum concentrations (Cmax) of fumarates 
in patients are usually within the range of 10‒15μmol/
L[19], whereas many preclinical studies have examined 
fumarate concentrations ≥40-fold this concentration 
(Table 1). In addition, the short in vivo half-life of 
fumarates needs to be considered. DMF is rapidly 
hydrolysed by esterases to MMF, the active metabolite, 
which is further metabolized into water and carbon 
dioxide[20]. DMF has a half-life of about 12 min[20], 
whereas that of MMF has been reported to be <40 
minutes[19]. Peak concentrations of MMF are reported to 
occur between 2.5 and 6 hours[19,20].
FAE Effects on Inflammatory Pathways
The effects of FAEs on inflammatory pathways have 
been studied in some depth. FAEs incubated with 
activated primary human peripheral blood mononuclear 
cells (PBMCs) have been reported to have differential 
effects on the secretion of inflammatory cytokines[13]. 
While DMF (1–100 µmol/L) and diethyl fumarate 
(DEF) exhibited potent suppression of tumour necrosis 
factor alpha (TNFα), interleukin (IL)-12 and type II 
interferon (IFNγ), fumaric acid (FA) and MEF (also 
known as ethylhydrogen fumarate [EHF]) did not 
display this inhibitory activity. Similarly, inhibition 
of IL-6, IFNγ and the keratinocyte growth factor 
transforming growth factor alpha (TGF-α), as well as 
stimulation of IL-10 secretion have been reported in 
activated human lymphocytes and keratinocytes co-
cultured in the presence of DMF (but not MEF)[21]. In 
addition, inhibition of allo-reactive T-cell proliferation 
in a mixed leucocyte reaction was only observed in the 
presence of DMF and DEF[13]. The immunosuppressive 
effects of FAEs as demonstrated here were reported 
alongside a marked induction of heme oxygenase (HO-
1), an anti-inflammatory stress protein. Induction of 
HO-1 and anti-inflammatory effects were blocked upon 
addition of glutathione (GSH), a known ligand of DMF. 
Furthermore, inhibition of HO-1 restored the previously 
diminished IL-12 and IFNγ production observed 
following treatment with FAEs[13]. More recently, 
further in vitro experiments in macrophages, PBMCs, 
HEK293 and HeLa cells have provided more evidence 
for the inhibitory effects of DMF (at concentrations 
ranging from 25–100 µM) on T-cytokine induction and 
its subsequent immunosuppressive activities (Table 1)
[15,17,18]. 
Studies by Nibbering and colleagues in human 
granulocytes have reported several effects mediated 
by MMF, the main metabolite produced following 
DMF ingestion (Table 1). MMF actions included 
inhibition of formylated peptide-induced respiratory 
burst and enhanced cellular polarization, cAMP 
production and calcium mobilization[4,22]. MMF has 
also been shown to stimulate IL-4 and IL-5 in a dose-
dependent manner when incubated with stimulated 
PBMCs; incubation with MMF had no effect on levels 
of IL-2, IFNγ or proliferative T-cell responses in these 
cultures[6]. Likewise, incubation of activated PBMCs 
and monocytes with MMF has been shown to stimulate 
activity of IL-10, TNF-α and IL-1 receptor antagonist 
(IL-1RA) independently of IL-12 secretion[23]. 
However, MMF activity has not been reported in 
all in vitro studies of this kind. In particular, MMF 
has shown no activity (compared with DMF) in 
studies that explored inhibition of nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-
кB)-dependent cytokine production by PBMCs[9,13], 
lymphocyte proliferation[13] or leucocyte-endothelial cell 
interactions[14].
Conversely, experiments in murine splenocyte cells 
have implicated DMF in the regulation of the NF-кB 
pathway and subsequent inflammatory pathways[9,24]. 
DMF has been shown to inhibit  NF-кB driven 
production of cytokines and suppress translocation of 
p65 and p52 in a nuclear factor erythroid-derived 2 (Nrf-
2)-independent manner. These effects were not seen 
with MMF or MEF. Modulation of the NF-кB pathway 
in this manner resulted in downstream suppression of 
inflammatory cytokine production, altered maturation 
and function of antigen-presenting cells, and immune 
deviation of T-helper cells (Th) from Th1 to Th17 
profiles to a Th2 phenotype[9]. Changes in cytokine 
profile from a Th1 to Th2 phenotype, in combination 
with T-cell inhibition, have also been reported in 
humans[25,26]. 
In vitro studies in human endothelial cells have 
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established a role for DMF in tissue factor expression. 
Loewe and colleagues observed that  DMF can 
selectively prevent the TNF-induced entry of NF-кB 
proteins into the nucleus. Furthermore, this effect was 
selective for NF-кB protein downstream of IкB kinase 
release, as shuttling of NF-кB/IкB complexes was not 
affected by DMF[27]. Furthermore, addition of NF-кB 
inhibitors augmented the anti-inflammatory potential 
of DMF. DMF-dependent inhibition of nuclear NF-кB 
translocation in TNF-α-stimulated human endothelial 
cells was greatly enhanced by blocking NF-кB activation 
via a kinase inhibitor of NF-кB-1 (KINK-1), a small 
molecule inhibitor of inhibitory кB kinase complex 
(IKKβ)[28]. These changes resulted in downstream 
reductions in the expression of endothelial adhesion 
molecules, including E-selectin, vascular cell adhesion 
protein 1 (VCAM-1) and intracellular adhesion molecule 
1 (ICAM-1) (key factors associated with leucocyte 
extravasation), such that rolling and adhesion of human 
lymphocytes on TNF-activated endothelial cells was 
synergistically reduced in this system[28].
Finally, incubation of neutrophil polymorphonuclear 
granulocytes (PMN, the first cells to infiltrate psoriatic 
plaques[29]) with DMF (10–20 µg/mL) has been shown 
to have inhibitory effects on neutrophil extracellular 
trap (NET) formation[30]. NETs initiate downstream 
inflammatory pathways including IL-1β dependent 
pathways and activation of Th17 cells[31], and NETs 
have thus been implicated as a key driver of psoriatic 
pathogenesis. Modulation of NET formation by DMF 
was glutathione-dependent and established via a 
reduction in reactive oxygen species (ROS). Inhibition 
of NET formation was not reported following treatment 
with MMF, and there was only a small reduction in ROS 
production[30].  DMF inhibition of NET formation may 
therefore contribute to the beneficial role of DMF in the 
management of psoriasis. 
In summary, DMF appears to have significantly greater 
inhibitory effects on many aspects of inflammatory 
processes in vitro than other FAEs, and particularly 
MEF. These effects have been reported consistently in 
in vitro studies with near-physiological concentrations 
of DMF, whereas results in studies of MMF have been 
inconsistent. Furthermore, only DMF has been shown 
to inhibit NET formation, which is proposed to be a key 
driver of psoriatic pathogenesis.
Antiproliferative and Cytotoxic Profile of 
FAEs
Early experiments in the mid-1970s identified a role for 
MEF in cellular processes. Inhibitory activity of MEF 
was reported by both Hagedorn et al.[2] and Petres et al.[3] 
in the context of DNA synthesis, cell proliferation and 
protein synthesis. Experiments in human lymphocytes 
and human PHA-stimulated lymphocytes incubated with 
varying concentrations of MEF all reported inhibition of 
these cellular processes with this FAE.
Subsequently, Thio and colleagues also reported 
dose-dependent inhibitory effects for the FAEs on cell 
proliferation in cultured keratinocytes. The potency of 
inhibitory action of different FAEs varied, with DMF 
showing the highest potency, followed by MEF and 
MMF[10]. FA reported the lowest inhibitory potential[10]. 
The antiproliferative effects of the FAEs were attributed 
to modulation of calcium ion release from intracellular 
stores into the cytoplasm[10]. Similarly, antiproliferative 
effects of DMF in cultured hyperproliferative HaCaT 
keratinocytes have been reported[5]; 50% inhibition 
concentrations (IC50) for DNA/protein synthesis 
were 2.3/2.5 μmol/L for DMF, 133/145 μmol/L, 215/ 
230 μmol/L and 275/270 μmol/L for zinc, calcium 
and magnesium salts of MEF, respectively, and 
>960 μmol/L for FA[5]. A similar cytotoxic potency 
profile was observed following incubation of FAEs 
(at concentrations ranging from 3–100 μmol/L) with 
lympho-histiocytic U-937 cells. DMF showed the largest 
dose-dependent apoptotic effect, followed by the zinc 
and calcium salts of MEF. No apoptotic activity was 
observed with FA and the magnesium salt of MEF at 
concentrations <100 μmol/L[12].
In summary, the most active FAE in terms of in vitro 
antiproliferative and cytotoxic effects is DMF. IC50s for 
the effects of DMF in vitro are in the same range as the 
serum concentrations observed in clinical studies, which 
is not the case for other FAEs.
FAE Effects on Antioxidant and Neu ro pro­
tec tive Pathways
The FAEs can activate the Nrf-2 pathway, which 
is considered to represent an endogenous defence 
mechanism against oxidative stress[8,32,33]. Under 
physiological conditions, Nrf-2 is sequestered in the 
cytoplasm by the kelch-like ECH-associated protein 
1 (KEAP1) so that it may be targeted for ubiquitation 
and subsequent proteasomal degradation[34,35]. Under 
conditions of oxidative stress, or in the presence of 
electrophiles, an allosteric conformational change in 
KEAP1 cysteine residues diminishes Nrf-2 degradation 
such that it can translocate into the nucleus and regulate 
cytoprotective genes associated with an antioxidant 
response[36,37]. In vitro studies by Brennan and colleagues 
found that treatment of human embryonic kidney 293 
cells with DMF (exhibiting electrophilic activity) 
modified KEAP1 cysteine residues, while such changes 
following treatment with MEF were significantly smaller 
and/or undetectable[8]. Modification of KEAP1 with 
DMF treatment was associated with nuclear translocation 
of Nrf-2 and a downstream transcriptional response in 
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treated cells. As before, these effects occurred to a lesser 
extent on incubation with MEF[8]. Acute concentration-
dependent depletion of GSH was also reported with DMF 
treatment; however, levels recovered above baseline 
within 24 hours. GSH reduction was not observed with 
MEF, and increased GSH levels above baseline were still 
observed at 24 hours[8]. More recently, work by Helwa 
and colleagues has reported that MMF can stimulate Nrf-
2 and aquaporin-3 (AQP3) expression in primary mouse 
keratinocytes and modulate downstream keratinocyte 
functionality[16]. Previous studies have found evidence 
for a role of AQP3 in keratinocyte differentiation[38,39] 
and may offer a means by which the effects of MMF on 
keratinocytes are mediated[16].
Neuroprotective effects of the FAEs on glial cells 
and neurons[32], and suppression of IL-12 and IL-
23 production by dendritic cells[40], have also been 
documented. Application of DMF to murine neuronal 
cells in vitro has been found to enhance survival and 
protect rodent or human astrocyte cells from oxidative 
stress via activation of the Nrf-2 pathway[32]. Similarly, 
like DMF, sulforaphane (SFN) is an immune-modulating 
compound derived from natural products and has been 
shown to suppress expression of IL-23 and IL-12 in 
vivo and augmented Th17- and Th1-mediated responses 
within the central nervous system[40]. 
Both DMF and MMF appear to have antioxidant 
effects in vitro, while MEF does not. DMF also has 
neuroprotective effects at physiological concentrations. 
FAE Effects on Cell­Adhesion Molecules
Other actions of DMF that have been reported in the 
literature (Table 1), include modulation of ICAM-
1, E-selectin and VCAM-1 expression[4,7,11,14]. In 
human umbilical vein endothelial cells (HUVECs), 
Vandermeeren and colleagues reported reduced 
expression of ICAM-1, VCAM-1 and E-selectin 
following incubation with DMF. In contrast, MEF and 
FA had no effect on expression of these molecules[7]. 
In another study, incubation of HUVECs and human 
lymphocytes with DMF, but not with MMF, also 
resulted in inhibition of expression of ICAM-1, VCAM-
1 and E-selection. This study also reported inhibition 
of leucocyte/endothelial cell interactions such as 
cell rolling and adhesion[14]. Finally, IFNγ-induced 
expression of ICAM-1 and human leucocyte antigen-DR 
(HLA-DR) on hyperproliferative HaCaT keratinocytes 
was suppressed with subtoxic concentrations of DMF 
and provides further support for the role of DMF in 
modulation of cell adhesion[11]. As described previously, 
regulation of NF-кB signalling by DMF in endothelial 
cells has been shown to have downstream consequences 
for cell-adhesion molecule signalling expression[28].
FAE Effects on Angiogenesis
It has also been postulated that FAEs may have an 
anti-angiogenic component to their functionality[41–43]. 
DMF was found to decrease tube formation in human 
endothelial cells in vitro. Cells treated with DMF had 
decreased expression of vascular endothelial growth 
factor receptor-2 (VEGFR-2), but not VEGFR-1 or 
neuropilin-1[43]. Other investigators also demonstrated 
tube formation inhibition with DMF but not with 
MMF or FA[42]. DMF also did not inhibit the kinase 
activity of VEGFR-2, and anti-angiogenic activity was 
demonstrated in two in vivo models[42]. DMF was shown 
in these models (chick chorioallantoic membrane and 
live fluorescent zebrafish embryo neovascularization 
assays) to attenuate the differentiation, proliferation and 
migration of endothelial cells and in doing so to block 
angiogenesis pathways. As observed previously, these 
effects were not replicated with MEF or FA. Inhibition 
of growth in transformed and untransformed cells by 
DMF has been postulated to occur via induction of 
apoptosis[42].
Conclusions
Overall, in vitro evidence to date indicates that MEF 
salts have less biological activity than DMF and 
MMF[5,13,14,21,44,45], as well as differing pharmacodynamic 
characteristics compared with DMF[46] (Table 1). The 
in vitro data justify the hypothesis that DMF is the key 
ingredient of Fumaderm® and mainly or even exclusively 
responsible for its antipsoriatic activity. This conclusion 
is supported by the results of animal experiments, which 
we have reviewed recently (Landeck et al., submitted). 
Most importantly, however, this conclusion has been 
proven by a double-blind, randomized, placebo-
controlled phase III clinical study demonstrating that 
DMF is as effective as Fumaderm® for the treatment of 
moderate-to-severe psoriasis[47].
Conflict of Interest
LL has no conflicts of interest to declare. AA and 
IPC are employees of Almirall, S.A. KA has served 
as consultant, advisory board member, or speaker for 
AbbVie, Antabio, Almirall, EmertiPharma, Galderma, 
Leo, Loreal, Eli Lilly, and Novartis. 
Acknowledgment
Medical writing assistance was provided by Sandra 
Cuscó PhD of Bioscript Group, Macclesfield, UK and 
was funded by Almirall S.A.
References
1. Nimmesgern E, Benediktsson I, Norstedt I, 2017, Personalized 
medicine in Europe. Clinical and Translational Science, 
Identifying the active pharmaceutical ingredient from a mixture of fumaric acid esters for the treatment of psoriasis: Hints from in vitro investigations
8    Advances in Precision Medicine (2017), Volume 2, Issue 1 
vol.10(2): 61–63. 
https://dx.doi.org/10.1111/cts.12446
2. Hagedorn M, Kalkoff K W, Kiefer G,  et  al . ,  1975, 
Fumarsäuremonoäthylester: Wirkung auf DNA-synthese und 
erste tierexperimentelle befunde (German) [Fumaric acid 
monoethylester: Effect on DNA-synthesis and preliminary 
findings in experimental studies in animals]. Archives of 
Dermatological Research, vol.254(1): 67–73. 
https://dx.doi.org/10.1007/BF00561536
3. Petres J, Kalkoff K W, Baron D, et al., 1975, Der Einfluss 
von Fumarsäuremonoäthylester auf die Nucleinsäure- und 
Proteinsynthese PHA-stimulierter menschlicher Lymphocyten 
(German) [The effect of fumaric acid monoethylester on the 
synthesis of nucleic acids and proteins of PHA-stimulated 
human lymphocytes]. Archiv fur Dermatologische Forschung, 
vol.251(4): 295–300. 
https://dx.doi.org/10.1007/BF00562233
4. Nibbering P H, Thio B, Zomerdijk T P, et al., 1993, Effects 
of monomethylfumarate on human granulocytes. Journal of 
Investigative Dermatology, vol.101(1): 37–42. 
https://dx.doi.org/10.1111/1523-1747.ep12358715
5. Sebok B, Bonnekoh B, Geisel J, et al.,1994, Antiproliferative 
and cytotoxic profiles of antipsoriatic fumaric acid derivatives 
in keratinocyte cultures. European Journal of Pharmacology, 
vol.270(1): 79–87. 
https://dx.doi.org/10.1016/0926-6917(94)90083-3
6. de Jong R, Bezemer A C, Zomerdijk T P, et al.,1996, Selective 
stimulation of T helper 2 cytokine responses by the anti-
psoriasis agent monomethylfumarate. European Journal of 
Immunology, vol.26(9): 2067–2074.
https://dx.doi.org/10.1002/eji.1830260916
7. Vandermeeren M, Janssens S, Borgers M, et al., 1997, 
Dimethylfumarate is an inhibitor of cytokine-induced 
E-selectin, VCAM-1, and ICAM-1 expression in human 
endothelial cells. Biochemical and Biophysical Research 
Communications, vol.234(1): 19–23.
https://dx.doi.org/10.1006/bbrc.1997.6570
8. Brennan M S, Matos M F, Li B, et al., 2015, Dimethyl 
fumarate and monoethylfumarate exhibit differential effects on 
KEAP1, NRF2 activation, and glutathione depletion in vitro. 
PLoS One, vol.10(3): e0120254. 
https://dx.doi.org/10.1371/journal.pone.0120254
9. Gillard G O, Collette B, Anderson J, et al., 2015, DMF, but 
not other fumarates, inhibits NF-kappaB activity in vitro in 
an Nrf2-independent manner. Journal of Neuroimmunology, 
vol.283: 74–85. 
https://dx.doi.org/10.1016/j.jneuroim.2015.04.006
10. Thio H B, Zomerdijk T P, Oudshoorn C, et al., 1994, Fumaric 
acid derivatives evoke a transient increase in intracellular free 
calcium concentration and inhibit the proliferation of human 
keratinocytes. British Journal of Dermatology, vol.131(6): 
856–861. 
https://dx.doi.org/10.1111/j.1365-2133.1994.tb08589.x
11. Sebok B, Bonnekoh B, Vetter R, et al., 1998, The antipsoriatic 
dimethyl-fumarate suppresses interferon-gamma-induced 
ICAM-1 and HLA-DR expression on hyperproliferative 
keratinocytes. Quantification by a culture plate-directed 
APAAP-ELISA technique. European Journal of Dermatology, 
vol.8(1): 29–32.
12. Sebök B, Gollnick H, Mahrle G, et al., 2000, Dimethyl-
fu marate is the Fumaderm-compound with the strongest 
induction of apoptosis-phenomena in lympho-histiocytic 
U-937 cells. Zeitschrift fur Hautkrankheiten, vol.76: 347–351.
13. Lehmann J C, Listopad J J, Rentzsch C U, et al., 2007, 
Dimethylfumarate induces immunosuppression via glutathione 
depletion and subsequent induction of heme oxygenase 1. 
Journal of Investigative Dermatology, vol.127(4): 835–845. 
https://dx.doi.org/10.1038/sj.jid.5700686
14. Wal lb rech t  K ,  Dr i ck  N ,  Hund  A C ,  e t  a l . ,  2011 , 
Downregulation of endothelial adhesion molecules by 
dimethylfumarate, but not monomethylfumarate, and 
impairment of dynamic lymphocyte-endothelial cell 
interactions. Experimental Dermatology, vol.20(12): 980–985. 
https://dx.doi.org/10.1111/j.1600-0625.2011.01376.x
15. McGuire V A, Ruiz-Zorrilla Diez T, Emmerich C H, et al., 
2016, Dimethyl fumarate blocks pro-inflammatory cytokine 
production via inhibition of TLR induced M1 and K63 
ubiquitin chain formation. Scientific Reports, vol.6(31159): 
31159. 
https://dx.doi.org/10.1038/srep31159
16. Helwa I, Choudhary V, Chen X, et al., 2017, The anti-
psoriatic drug monomethylfumarate increases nuclear 
factor erythroid 2-related factor 2 (Nrf2) levels and induces 
aquaporin-3 (AQP3) mRNA and protein expression. Journal 
of Pharmacology and Experimental Therapeutics,vol.362(2): 
243–253.
https://dx.doi.org/10.1124/jpet.116.239715
17. Ghoreschi K, Bruck J, Kellerer C, et al., 2011, Fumarates 
improve psoriasis and multiple sclerosis by inducing 
type II dendritic cells. Journal of Experimental Medicine, 
vol.208(11): 2291–2303. 
https://dx.doi.org/10.1084/jem.20100977
Landeck L, et. al.
    Advances in Precision Medicine (2017), Volume 2, Issue 1  9
18. Tahvili S, Zandieh B, Amirghofran Z, 2015, The effect 
of dimethyl fumarate on gene expression and the level 
of cytokines related to different T helper cell subsets in 
peripheral blood mononuclear cells of patients with psoriasis. 
International Journal of Dermatology, vol.54(7): e254–260. 
https://dx.doi.org/10.1111/ijd.12834
19. Rostami-Yazdi  M,  Clement  B,  Mrowietz  U,  2010, 
Pharmacokinetics of anti-psoriatic fumaric acid esters in 
psoriasis patients. Archives of Dermatological Research, 
vol.302(7): 531–538. 
https://dx.doi.org/10.1007/s00403-010-1061-4
20. Mrowietz U, Christophers E, Altmeyer P, 1999, Treatment 
of severe psoriasis with fumaric acid esters: Scientific 
background and guidelines for therapeutic use. British Journal 
of Dermatology, vol.141(3): 424–429. 
https://dx.doi.org/10.1046/j.1365-2133.1999.03034.x
21. Ockenfels H M, Schultewolter T, Ockenfels G, et al., 1998, 
The antipsoriatic agent dimethylfumarate immunomodulates 
T-cell cytokine secretion and inhibits cytokines of the psoriatic 
cytokine network. British Journal of Dermatology, vol.139(3): 
390–395. 
https://dx.doi.org/10.1046/j.1365-2133.1998.02400.x
22. Nibbering P H, Thio B, Bezemer A C ,  et al. ,  1997, 
Intracellular signalling by binding sites for the antipsoriatic 
agent monomethylfumarate on human granulocytes. British 
Journal of Dermatology, vol.137(1): 65–75. 
https://dx.doi.org/10.1046/j.1365-2133.1997.1769185.x
23. Asadullah K, Schmid H, Friedrich M, et al., 1997, Influence 
of monomethylfumarate on monocytic cytokine formation-
explanation for adverse and therapeutic effects in psoriasis? 
Archives of Dermatological Research, vol.289(11): 623–630. 
https://dx.doi.org/10.1007/s004030050251
24. Gillard G, Huss D, Anderson J, et al., 2014, Fumarate 
esters are distinguished by differential inhibition of the NF-
κB mediated proinflammatory response. Minerva Medica, 
vol.52(2): 428
25. Menter A, Korman N J, Elmets C A, et al., 2009, Guidelines 
of care for the management of psoriasis and psoriatic arthritis. 
Section 3. Guidelines of care for the management and 
treatment of psoriasis with topical therapies. Journal of the 
American Academy of Dermatology, vol.60(4): 643–659. 
https://dx.doi.org/10.1016/j.jaad.2009.03.027
26. Hoxtermann S, Nuchel C, Altmeyer P, 1998, Fumaric 
acid esters suppress peripheral CD4- and CD8-positive 
lymphocytes in psoriasis. Dermatology, vol.196(2): 223–230. 
https://dx.doi.org/10.1159/000017903
27. Loewe R,  Holnthoner  W,  Groger  M,  e t  a l . ,  2002, 
Dimethylfumarate inhibits TNF-induced nuclear entry of 
NF-kappa B/p65 in human endothelial cells. Journal of 
Immunology, vol.168(9): 4781–4787. 
https://dx.doi.org/10.4049/jimmunol.168.9.4781
28. Hund A C, Lockmann A, Schon M P, 2016, Mutually 
enhancing anti-inflammatory activities of dimethyl fumarate 
and NF-kappaB inhibitors-implications for dose-sparing 
combination therapies. Experimental Dermatology, vol.25(2): 
124–130. 
https://dx.doi.org/10.1111/exd.12892
29. Christophers E, Metzler G, Rocken M, 2014, Bimodal immune 
activation in psoriasis. British Journal of Dermatology, 
vol.170(1): 59–65. 
https://dx.doi.org/10.1111/bjd.12631
30. Hoffmann JHO, Schaekel K, Hartl D, et al., 2017, Dimethyl 
fumarate modulates neutrophil extracellular trap formation 
in a glutathione and superoxide-dependent manner. British 
Journal of Dermatology. 
https://dx.doi.org/10.1111/bjd.15839
31. Warnatsch A, Ioannou M, Wang Q, et al., 2015, Inflammation. 
Neutrophil extracellular traps license macrophages for 
cytokine production in atherosclerosis. Science, vol.349(6245): 
316–320. 
https://dx.doi.org/10.1126/science.aaa8064
32. Linker R A, Lee D H, Ryan S, et al., 2011, Fumaric acid 
esters exert neuroprotective effects in neuroinflammation via 
activation of the Nrf2 antioxidant pathway. Brain, vol.134(Pt 
3): 678–692. 
https://dx.doi.org/10.1093/brain/awq386
33. Scannevin R H, Chollate S, Jung M Y, et al., 2012, Fumarates 
promote cytoprotection of central nervous system cells against 
oxidative stress via the nuclear factor (erythroid-derived 2)-
like 2 pathway. Journal of Pharmacology and Experimental 
Therapeutics, vol.341(1): 274–284. 
https://dx.doi.org/10.1124/jpet.111.190132
34. Itoh K, Wakabayashi N, Katoh Y, et al., 2003, Keap1 regulates 
both cytoplasmic-nuclear shuttling and degradation of Nrf2 in 
response to electrophiles. Journal of Genes to Cells, vol.8(4): 
379–391.
https://dx.doi.org/10.1046/j.1365-2443.2003.00640.x
35. Kobayashi A, Kang M I, Okawa H, et al., 2004, Oxidative 
stress sensor Keap1 functions as an adaptor for Cul3-based E3 
ligase to regulate proteasomal degradation of Nrf2. Molecular 
and Cellular Biology, vol.24(16): 7130–7139. 
https://dx.doi.org/10.1128/MCB.24.16.7130-7139.2004
Identifying the active pharmaceutical ingredient from a mixture of fumaric acid esters for the treatment of psoriasis: Hints from in vitro investigations
10    Advances in Precision Medicine (2017), Volume 2, Issue 1 
36. Itoh K, Chiba T, Takahashi S, et al., 1997, An Nrf2/small Maf 
heterodimer mediates the induction of phase II detoxifying 
enzyme genes through antioxidant response elements. 
Biochemical and Biophysical Research Communications, 
vol.236(2): 313–322. 
https://dx.doi.org/10.1006/bbrc.1997.6943
37. Nguyen T, Sherratt PJ, Pickett C B, 2003, Regulatory 
mechanisms controlling gene expression mediated by 
the antioxidant response element. Annual Review of 
Pharmacology and Toxicology, vol.43: 233–260. 
https://dx.doi.org/10.1146/annurev.pharmtox.43.100901.1402 
29
38. Bollag W B, Xie D, Zheng X, et al., 2007, A potential role 
for the phospholipase D2-aquaporin-3 signaling module 
in early keratinocyte differentiation: production of a 
phosphatidylglycerol signaling lipid. Journal of Investigative 
Dermatology, vol.127(12): 2823–2831. 
https://dx.doi.org/10.1038/sj.jid.5700921
39. Choudhary V, Olala L O, Qin H, et al., 2015, Aquaporin-3 
re-expression induces differentiation in a phospholipase 
D2-dependent manner in aquaporin-3-knockout mouse 
keratinocytes. Journal of Investigative Dermatology, 
vol.135(2): 499–507. 
https://dx.doi.org/10.1038/jid.2014.412
40. Geisel J, Bruck J, Glocova I, et al., 2014, Sulforaphane 
protects from T cell-mediated autoimmune disease by 
inhibition of IL-23 and IL-12 in dendritic cells. Journal of 
Immunology, vol.192(8): 3530–3539. 
https://dx.doi.org/10.4049/jimmunol.1300556
41. Arbiser J L, 2011, Fumarate esters as angiogenesis 
inhibitors: Key to action in psoriasis. Journal of Investigative 
Dermatology, vol.131(6): 1189–1191. 
https://dx.doi.org/10.1038/jid.2011.45
42. Garcia-Caballero M, Mari-Beffa M, Medina MA, et al., 
2011, Dimethylfumarate inhibits angiogenesis in vitro and 
in vivo: A possible role for its antipsoriatic effect? Journal of 
Investigative Dermatology, vol.131(6): 1347–1355. 
https://dx.doi.org/10.1038/jid.2010.416
43. Meissner M, Doll M, Hrgovic I, et al., 2011, Suppression 
of VEGFR2 expression in human endothelial cells by 
dimethylfumarate treatment: Evidence for anti-angiogenic 
action. Journal of Investigative Dermatology, vol.131(6): 
1356–1364. 
https://dx.doi.org/10.1038/jid.2011.46
44. Treumer F, Zhu K, Glaser R, et al., 2003, Dimethylfumarate 
is a potent inducer of apoptosis in human T cells. Journal of 
Investigative Dermatology, vol.121(6): 1383–1388. 
https://dx.doi.org/10.1111/j.1523-1747.2003.12605.x
45. R u b a n t  S  A ,  L u d w i g  R  J ,  D i e h l  S ,  e t  a l . ,  2 0 0 8 , 
Dimethylfumarate reduces leukocyte rolling in vivo through 
modulation of adhesion molecule expression. Journal of 
Investigative Dermatology, vol.128(2): 326–331. 
https://dx.doi.org/10.1038/sj.jid.5700996
46. Brennan M, Allaire N, Huss D, et al., 2014, Dimethyl 
fumarate and monomethyl fumarate are distinguished by non-
overlapping pharmacodynamic effects in vivo. Neurology, 
vol.82: P1.206.
47. Mrowietz U, Szepietowski J C, Loewe R, et al., 2017, Efficacy 
and safety of LAS41008 (dimethyl fumarate) in adults with 
moderate-to-severe chronic plaque psoriasis: A randomized, 
double-blind, Fumaderm(R)- and placebo-controlled trial 
(BRIDGE). British Journal of Dermatology, vol.176(3): 615–
623. 
https://dx.doi.org/10.1111/bjd.14947
